» Articles » PMID: 23595591

Calretinin is Essential for Mesothelioma Cell Growth/survival in Vitro: a Potential New Target for Malignant Mesothelioma Therapy?

Overview
Journal Int J Cancer
Specialty Oncology
Date 2013 Apr 19
PMID 23595591
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant mesothelioma (MM) are highly aggressive asbestos-related neoplasms, which show strong chemotherapy resistance, and there is no effective cure for MM so far. Calretinin (CR) is widely used as a diagnostic marker for epithelioid and mixed (biphasic) mesothelioma; however, little is known about CR's putative functions in tumorigenesis. CR protects against asbestos-induced acute cytotoxicity mediated by the AKT/PI3K pathway, and furthermore, SV40 early region genes are able to upregulate CR in mesothelial cells. However, the precise role of CR in mesothelioma is still unknown. Downregulation of CR via lentiviral-mediated short-hairpin RNA significantly decreased the viability and proliferation of mesothelioma cells in vitro. The effect was strong in epithelioid-dominated cell lines (ZL55 and MSTO-211H). A weaker and delayed effect was observed in mesothelioma cells with prevalent sarcomatoid morphology (SPC111, SPC212 and ZL34). The specificity of the effect was confirmed by stable enhanced green fluorescent protein-CR expression in mesothelioma cell lines and subsequent downregulation. Depletion of CR led these cancer cell lines to enter apoptosis within 72 hr postinfection via strong activation of the intrinsic caspase 9-dependent pathway. Downregulation of CR in immortalized mesothelial cells LP9/TERT-1 strongly blocked proliferation and caused a G1 block without decreasing viability or activating apoptosis pathways. These results demonstrate that downregulation of CR had a strong effect on the viability of MM cells and that CR is essential for cells derived from MM. The authors anticipate these findings to reveal CR as a highly interesting new putative therapeutic target for mesothelioma treatment of especially the epithelioid, as well as of the mixed and sarcomatoid type.

Citing Articles

Insights into the mechanisms driven by H3K4 KMTs in pancreatic cancer.

LaRue-Nolan K, Raja Arul G, Sigafoos A, Shi J, Fernandez-Zapico M Biochem J. 2024; 481(15):983-997.

PMID: 39078225 PMC: 11332384. DOI: 10.1042/BCJ20230374.


Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.

Rigon M, Mutti L, Campanella M Mol Oncol. 2024; 18(4):797-814.

PMID: 38459714 PMC: 10994233. DOI: 10.1002/1878-0261.13591.


BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.

Yuce T, Ak G, Metintas S, Dundar E, Roe O, Panou V J Cancer Res Clin Oncol. 2024; 150(2):38.

PMID: 38280040 PMC: 10821830. DOI: 10.1007/s00432-023-05565-6.


CSTF2T facilitates pancreatic adenocarcinoma growth and metastasis by elevating H3K4Me1 methylation of CALB2 via ASH2L.

Liu W, Hu D, Li J, Xu Q, Chen Z, Xu B Cancer Biol Ther. 2023; 24(1):2216041.

PMID: 37287122 PMC: 10251778. DOI: 10.1080/15384047.2023.2216041.


Serum Calretinin as a Biomarker in Malignant Mesothelioma.

Zupanc C, Franko A, Strbac D, Fikfak M, Kovac V, Dolzan V J Clin Med. 2021; 10(21).

PMID: 34768395 PMC: 8585060. DOI: 10.3390/jcm10214875.